Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 9/20 | 0.47 |
| ▸ | LRRK2 | Q5S007 | 4/20 | 0.47 |
| ▸ | PIM3 | Q86V86 | 2/20 | 0.43 |
| ▸ | RAF1 | P04049 | 1/20 | 0.40 |
| ▸ | FYN | P06241 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 2/20 | 0.38 |
| ▸ | PIM1 | P11309 | 1/20 | 0.36 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2934386 | 0.95 | BRAF (0.48) | BRAFLRRK2PIM3RAF1FYN | |
| SCHEMBL2930611 | 0.88 | FYN (0.50) | BRAFLRRK2PIM3RAF1FYN | |
| SCHEMBL2933758 | 0.86 | KDR (0.49) | BRAFLRRK2PIM3RAF1FYN | |
| SCHEMBL2933849 | 0.83 | BRAF (0.56) | BRAFLRRK2PIM3RAF1 | |
| SCHEMBL2927734 | 0.81 | LRRK2 (0.44) | BRAFLRRK2PIM3 | |
| SCHEMBL2934249 | 0.80 | BRAF (0.45) | BRAFLRRK2PIM3RAF1KDR | |
| SCHEMBL2933495 | 0.79 | ADRA2A (0.52) | BRAFLRRK2PIM3 | |
| SCHEMBL2933983 | 0.78 | BRAF (0.48) | BRAFLRRK2PIM3RAF1 | |
| SCHEMBL2934782 | 0.78 | BRAF (0.43) | BRAFLRRK2PIM3RAF1 | |
| SCHEMBL2931521 | 0.76 | BRAF (0.42) | BRAFLRRK2PIM3RAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2044051-B1 | PYRIDINE AND PYRAZINE DERIVATIVES AS MNK KINASE INHIBITORS | BIOVITRUM AB PUBL (SE) | 2010-01-27 | — | — | EP | disclosed |
| EP-2044051-B1 | PYRIDINE AND PYRAZINE DERIVATIVES AS MNK KINASE INHIBITORS | BIOVITRUM AB PUBL (SE) | 2010-01-27 | — | — | EP | disclosed |
| US-20080039450-A1 | Compounds | BIOVITRUM AB (PUBL.) (SE) | 2008-02-14 | — | — | US | disclosed |
| US-20080039450-A1 | Compounds | BIOVITRUM AB (PUBL.) (SE) | 2008-02-14 | — | — | US | disclosed |
| US-20080039450-A1 | Compounds | BIOVITRUM AB (PUBL.) (SE) | 2008-02-14 | — | — | US | disclosed |
| WO-2007147874-A1 | PYRIDINE AND PYRAZINE DERIVATIVES AS MNK KINASE INHIBITORS | BIOVITRUM AB (PUBL) (SE) | 2007-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039450-A1 | Compounds | NEK2, CSNK2A3, CSNK2A1 | BRAF 524/4885LRRK2 309/4885PIM3 2131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.